Rhode Island H7187 prohibits insurers from requiring reviews for certain prescription medicines used to treat alcohol or opioid use disorder.
Rhode Island H7187 amends the Benefit Determination and Utilization Review Act to prohibit healthcare insurers from requiring or conducting a review for prescription medicines used in the treatment of alcohol or opioid use disorder. This includes medicines containing Methadone, Buprenorphine, or Naltrexone, or those approved to mitigate opioid withdrawal symptoms. The prohibition applies to health benefit plans issued or renewed on or after January 1, 2027.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.